Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 31;107(4):994–1003. doi: 10.1097/TP.0000000000004355

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

FIGURE 3. — Death-censored renal graft survival without eculizumab treatment. Kaplan-Meier analysis of overall renal graft survival in recipients transplanted between 1978 and 2016 for atypical hemolytic uremic syndrome who did not receive eculizumab treatment with the transplant. Survival is censored for patient death with a functioning graft and for functioning graft at last follow-up. Numbers at risk in each group at 12 monthly time points are detailed below the graph. A. Graft survival by complement defect. Grafts grouped by presence of autoantibodies against Factor H (anti-FH), variant of uncertain significance (VUS) or pathogenic variant in complement factor I (CFI), complement factor H (CFH), membrane cofactor protein (CD46), or C3 in recipient. B. Graft survival by risk of relapse. Grafts grouped by low, medium, or high risk of atypical hemolytic syndrome recurrence (as stratified by KDIGO)³ in the recipient.